AML Course 1 – Optimizing a personalized approach to AML therapy
Learn about the advances in AML diagnostics and risk assessment which prompted recent changes to the ELN recommendations and how these facilitate a personalized approach to AML therapy.
Charles Craddock
CBE, FRCP (UK), FRCPath, DPhil, FMedSciUniversity of Birmingham, Birmingham, United Kingdom
Eunice Wang
MDRoswell Park Comprehensive Cancer Center, Buffalo, NY, United States
- Educational Overview
- Speaker Info
- Evaluation & Accreditation
- Disclosures & Disclaimers
- Technical Support
Activity Description
This course will describe the advances in AML diagnostics and risk assessment which prompted the ELN 2022 recommendations and how the changes facilitate a personalized approach to AML therapy.
Learning Objectives
The overall aim of this set of 5 courses on AML is to:
- Evaluate current diagnostic and prognostic approaches in AML, examining elements of these in the light of the European LeukemiaNet (ELN) 2022 recommendations (Dohner et al 2022)
- Distil the overwhelming amount of data in AML into that which is clinically relevant following the ELN 2022 update, aligning available therapies/management strategies with patient needs
- Interpret current diagnostic testing and risk assessment guidance to enable personalized treatment of AML and to improve patient supportive care during diagnosis, treatment, and management of AML
Target Audience
This course is aimed at global healthcare professionals including general hematologists treating patients with AML.
Content Reviewer
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK
Charles Craddock
CBE, FRCP (UK), FRCPath, DPhil, FMedSciUniversity of Birmingham, Birmingham, United Kingdom
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci, is Professor of Hemato-oncology at the University of Birmingham, Birmingham, UK, and Academic Director of the Centre for Clinical Haematology at the Queen Elizabeth Hospital, Birmingham, UK.
Prof. Craddock qualified at the University of Oxford, Oxford, UK, first obtaining his undergraduate degree in Physiological Sciences in 1979, before completing his MBBCh and his DPhil in 1982 and 1994 respectively. He became a fellow of both the Royal College of Physicians and the Royal College of Pathologists in 2008. Prof. Craddock trained in hematology at the Hammersmith Hospital in London, UK, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, WA.
As Director of the BMT Unit at the Queen Elizabeth hospital in Birmingham, Prof. Craddock drove the establishment and subsequent expansion of the £7 million Centre for Clinical Haematology at the Queen Elizabeth Hospital and, as Director of Birmingham Health Partners, led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015.
Prof. Craddock is Chair of the NCRI Acute Myeloid Leukaemia Working Group and leads the UK Haemato-oncology Trials Acceleration Programme, as well as being elected President of the British Society of Haematology in 2017. He was awarded the CBE for services to medicine and medical research in the 2016 New Year’s Honours list.
Eunice Wang
MDRoswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Dr Wang is currently the Chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, Buffalo, NY, as well as an Associate Professor of Medicine at Jacobs School of Medicine & Biomedical Sciences, University of Buffalo, Buffalo, NY. Dr Wang is the recipient of several awards such as the Doris Duke “”Bench to Bedside”” Translational Research Award (2002), the Leukemia Lymphoma Society Patient Service Award (2007), and the NCI Cancer Clinical Investigator Team Leadership Award (2013).
Dr Wang obtained her medical degree from the Keck School of Medicine, University of Southern California, CA, and completed her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. From 1999 to 2003, she completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Dr Wang’s clinical research focuses on the development of early stage clinical trials for acute leukemias and myeloproliferative disorders. Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies.
- CME Accreditation Type
- ACCME – Amedco, see accreditation statement below
- CME Credits
- 0.5 CME credits
Requirement for Successful Completion
To complete this activity and obtain CME credits, participants must:
(1) complete the educational activity online, and;
(2) complete the post-test and activity evaluation.
Participants must receive a minimum score of 60% on the post-test.
Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
- Method Participation
- There are no fees to participate in this activity.
- Estimated Completion Time
- 30 minutes
| Disclosure Statement
The opinions expressed in this educational activity are those of the faculty, and do not necessarily represent the views of Magdalen Medical Publishing. This educational activity is intended to supplement existing knowledge, published information, and practice guidelines. Participants in this educational activity should critically appraise the information presented and draw conclusions only after careful consideration of all other available scientific information. Unapproved products or unapproved uses of approved products may be discussed by the faculty and these situations may reflect the approval status in one or more jurisdictions. Mention of these unapproved products or unapproved uses in this activity should not be considered an endorsement of these products or practices. For this e-learning course, speaker disclosures have been submitted to the accrediting body, Amedco; all speakers have received an honorarium from MMP for their participation in this activity. All educational materials have been reviewed for fair balance, scientific objectivity and appropriate levels of evidence. Acknowledgement of Financial Commercial Support This course is supported by medical educational support from Jazz Pharmaceuticals. The supporter has no influence over the production of the content. Acknowledgement of In-Kind Commercial Support Disclosure of Conflict of Interest Each individual in a position to control the content disclosed to Amedco all relevant financial relationships. All of these relationships were treated as a conflict of interest and have been resolved to ensure the content is un-biased. |
- Course Provider
- Magdalen Medical Publishing
- Contact Information
If you are experiencing technical difficulties, please contact support@vjhemonc.com and we will get back to you as soon as possible.
Hardware & Software Requirements
This module requires the participant to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS.
Functional sound capabilities are also required as some course media may include audio content.
How to Get Your Certificate
- Complete the post course assessment with a score of over 80%
- Click on the complete course button
- Evaluate the meeting
- Print, download, or save your certificate for your records
- If you need help, please contact support@vjhemonc.com
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC
and The Video Journal of Hematological Oncology. Amedco LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide
continuing education for the healthcare team. Amedco Joint Accreditation Provider Number: 4008163
PHYSICIANS (ACCME) CREDIT DESIGNATION STATEMENT
Amedco LLC designates this material for a maximum of 0.50 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACKNOWLEDGEMENT OF FINANCIAL COMMERCIAL SUPPORT
This course is supported by medical educational support from Jazz Pharmaceuticals. The supporter has no influence over the production of the content.
